ACI-7104, an investigational vaccine to treat people in the early stages of Parkinson’s disease, is showing safety and tolerability in a Phase 2 clinical trial, while also inducing the production of anti-alpha-synuclein antibodies at high levels, according to interim trial findings. Being developed by AC Immune,…
News
Crushed dried seeds of the jujube fruit, a traditional herbal medicine also known as Chinese or red date, eased the motor symptoms of Parkinson’s and helped with neurogenesis, the process by which new neurons are formed in the brain, in a mouse model of the disease. In a study led…
Vesalius Therapeutics has entered into an agreement with GSK to advance the development of new therapies for Parkinson’s disease and one other undisclosed neurodegenerative condition. Under the agreement, Vesalius will be responsible for identifying new treatment targets for the conditions, while GSK will have the option to…
The Critical Path Institute (C-Path) is launching a new initiative to advance research on how Parkinson’s disease impacts women and people across the gender spectrum. The goal is to develop treatments and technologies that take into account each person’s unique experience with the disease, leading to more equitable approaches for…
Higher levels of proteins called chaperones are linked with lower levels of disease-driving toxic protein clumps in the brains of people with Parkinson’s disease, a new study shows. The findings suggest that increasing chaperone proteins may be a viable therapeutic strategy for Parkinson’s. Data from the study also revealed…
Researchers have developed a method to detect clumps of alpha-synuclein protein, a hallmark of Parkinson’s disease, within extracellular vesicles (EVs) purified from blood, providing a possible aid to Parkinson’s diagnosis before symptoms appear. EVs are tiny membrane-bound sacs released from cells that can carry a variety of molecules, including…
People who received five or more courses of penicillin antibiotic treatment in the five years before a Parkinson’s diagnosis had an approximately 15% lower risk of developing the disease than those who took no antibiotics, according to a Rutgers Health study. Conversely, treatment with two or more courses of…
The planned Phase 2 SUNRISE-PD clinical trial of oral bezisterim as a first-line, stand-alone treatment for newly diagnosed Parkinson’s disease patients is scheduled to begin in early 2025. BioVie, the therapy’s developer, has secured over $15 million to cover complete costs of the trial, and top-line findings are…
Lianna Genovese, the 25-year-old founder of Imaginable Solutions and the inventor of Guided Hands, a device that helps individuals with limited hand mobility, was recognized with the 2024 Muhammad Ali Humanitarian Award. Various conditions can limit a person’s ability to write, draw, dress themselves, or use technology, including…
Zimmer Biomet announced that it has acquired select exclusive rights to distribute NeuroOne’s OneRF Ablation System, a brain electrode-guided tool for use in neurological brain surgeries, including those for Parkinson’s disease. “As the world’s first FDA [U.S. Food and Drug Administration] cleared system for both diagnostic…
Recent Posts
- AAN 2026: Switch to Vyalev stops troublesome dyskinesia in trial
- AAN 2026: Crexont linked to more on time in new Parkinson’s study
- Guest Voice: When Parkinson’s disease and bipolar disorder collide
- FDA approves next-gen wearable sensor for tremor control in Parkinson’s
- Amprion working to expand access globally to alpha-synuclein protein test